Should Deubiquitinating Enzymes be Targeted for Therapy?
|Sokol V Todi1* and Chittaranjan Das2|
|1Department of Pharmacology and Department of Neurology, Wayne State University School of Medicine, USA|
|2Department of Chemistry, Purdue University, USA|
|Corresponding Author :||Sokol V Todi
Assistant Professor, Department of Pharmacology and Department of Neurology
Wayne State University School of Medicine
540 E. Canfield, Scott Hall Rm 6105, Detroit
Michigan 48201, USA
|Received August 16, 2012; Accepted August 17, 2012; Published August 23, 2012|
|Citation: Todi SV, Das C (2012) Should Deubiquitinating Enzymes be Targeted for Therapy? Clinic Pharmacol Biopharm. 1:e108. doi:10.4172/2167-065X.1000e108|
|Copyright: © 2012 Todi SV, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.|
Effective, non-toxic therapies for many diseases, including malignancies, metabolic syndromes and age-dependent neurodegeneration remain elusive, though not for lack of effort from scientists all over the world.